When Valeant Pharmaceuticals reports its first quarter earnings on June 7, investors and analysts will pay attention to the results, the Wall Street Journal reports. The newspaper wrote that people will be interested to know how Valeant plans on paying down its $32 billion debt load and whether the company can meet its projections of $2.3 billion to $2.4 billion in revenue and $1.18 to $1.43 in adjusted earnings per share.
Since August 2015, Valeant’s share price has decreased nearly 90 percent, the Journal notes, as the federal government questioned the company’s business practices.
Read the full story below:
Executive Editor
Tim Casey joined TriMed Media Group in 2015 as Executive Editor. For the previous four years, he worked as an editor and writer for HMP Communications, primarily focused on covering managed care issues and reporting from medical and health care conferences. He was also a staff reporter at the Sacramento Bee for more than four years covering professional, college and high school sports. He earned his undergraduate degree in psychology from the University of Notre Dame and his MBA degree from Georgetown University.